Stemline Therapeutics KOL Event at ASH 2018

San Diego, CA, December 3, 2018

ASH_Investor_Invite_OTC_11_1_181_2_ruejdp.jpg

For more information or to RSVP, please email Alan Lada, alada@troutgroup.com

 

 

 

 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Stemline Therapeutics, Inc. [STML] US$340 MM MCap
3 clin­i­cal stage on­col­o­gy prod­uct can­di­dates. 1) EL­ZON­RIS is a tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123) pre­sent on range of ma­lig­nan­cies that suc­cess­ful­ly com­plet­ed a piv­o­tal trial in BPD­CN... [more in­for­ma­tion]

Event Contact

Alan Lada
Solebury Trout